CONMED Corporation Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- This is Morgan Stanley's only preferred sportswear stock
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- White House copper tariff plan stalls amid affordability concerns, sources say
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Northland Capital Markets Downgrades CONMED (CNMD) to Market Perform
July 22, 2015 7:19 AM EDTNorthland Capital Markets downgraded CONMED (NASDAQ: CNMD) from Outperform to Market Perform with a price target of $58.00 (from $65.00), saying 2nd-half guidance may be too optimistic.
Analyst Mark Landy commented, "CNMD reported in line 2Q revenues of $181M but missed our and the... More
Needham & Company Raises Price Target to $60 Following Conmed's (CNMD) 2Q Miss
July 22, 2015 6:58 AM EDTNeedham & Company reiterated a Buy rating on CONMED (NASDAQ: CNMD), and raised the price target to $60.00 (from $56.00), following 2Q15. CNMD's reported revenue was $181.0M vs. consensus of $182.3M. EPS was $0.36 vs. consensus of $0.44. Analyst Mike Matson said that investors may give management the benefit of... More
Conmed (CNMD) Misses Q2 EPS by 8c, Maintains FY15 Guidance
July 21, 2015 4:04 PM EDTConmed (NASDAQ: CNMD) reported Q2 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $181 million versus the consensus estimate of $182.6 million.
2015 Outlook
The Company reiterated its previously disclosed constant currency sales guidance, which calls... More
